Eli Lilly Message Board - Msg: 32771434

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly

LLY 1,057

+1.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Moonray	6/5/2020 4:17:52 PM
	of 642

Nektar sees 'encouraging trends' in early lupus trial Piper Sandler analyst Tyler Van Buren noted that Nektar (NKTR) management reported Phase 1b NKTR-358 data at the EULAR virtual meeting, including safety data and signals of dose-dependent inductions of Tregs with no effect on conventional T cells. While no data regarding the impact on lupus disease activity were disclosed, management noted "encouraging trends" were observed, according to Van Buren. The analyst, who noted that Nektar and partner Eli Lilly (LLY) will launch a Phase 2 trial in moderate-to-severe lupus patients "soon," keeps an Overweight rating on Nektar shares. o~~~ O

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next